Newtopia（NEWU.F）株式概要ニュートピア社は、主に米国で、テクノロジーを活用したホールヘルスプラットフォームとして事業を展開している。 詳細NEWU.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 株式の流動性は非常に低い 意味のある時価総額がありません ( $624K )すべてのリスクチェックを見るNEWU.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.000598.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-9m11m2016201920222025202620282031Revenue CA$6.7mEarnings CA$483.3kAdvancedSet Fair ValueView all narrativesNewtopia Inc. 競合他社Medical Care TechnologiesSymbol: OTCPK:MDCEMarket cap: US$975.1kNewGenIvf GroupSymbol: NasdaqCM:NIVFMarket cap: US$362.7kMobile-health Network SolutionsSymbol: NasdaqCM:MNDRMarket cap: US$2.9mAmerican Shared Hospital ServicesSymbol: NYSEAM:AMSMarket cap: US$8.8m価格と性能株価の高値、安値、推移の概要Newtopia過去の株価現在の株価CA$0.000552週高値CA$0.01952週安値CA$0.0001ベータ01ヶ月の変化0%3ヶ月変化0%1年変化n/a3年間の変化n/a5年間の変化-99.89%IPOからの変化-99.88%最新ニュースお知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.最新情報をもっと見るRecent updatesお知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.お知らせ • Nov 10Newtopia Inc. to Report Q3, 2023 Results on Nov 16, 2023Newtopia Inc. announced that they will report Q3, 2023 results After-Market on Nov 16, 2023お知らせ • Oct 17Newtopia Inc. announced that it has received CAD 0.805 million in fundingOn October 16, 2023, the company announced that it has received CAD 425,000 in its second tranche. The securities issued pursuant to the offering are subject to a four month hold period that expires on February 14, 2024. The debentures issued in connection with this second tranche of the offering will mature on October 13, 2024. The company paid a finder's fee of CAD 1,800 and 15,652 non-transferable compensation options. Each compensation option is exercisable into one common share at CAD 0.115 per share, subject to adjustments in certain events, until October 13, 2025.お知らせ • Aug 05Newtopia Inc. to Report Q2, 2023 Results on Aug 09, 2023Newtopia Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023お知らせ • Jun 29Newtopia Inc. announced that it expects to receive CAD 0.5 million in fundingNewtopia Inc. announced a non-brokered private placement of 13% 50 units of Subordinated Non-Convertible debentures at a price of CAD 10,000 for the gross proceeds of CAD 0.5 million on June 27, 2023. Each unit will be comprised of CAD10,000 principal amount of subordinated and postponed secured non-convertible debentures of the company and bonus shares. In the event that the maximum amount of debentures are issued in connection with the offering, a maximum of 1,538,461 bonus shares will be issuable in connection with the offering. The debentures will mature on the date that is 24 months from the closing date of the offering and are secured by the assets of the Company and bear interest at a rate of 13% per annum payable quarterly in arrears in cash. The company will pay to the holders of the debentures an annual work and credit maintenance fee of 2% of the principal amount in cash. The debentures and the bonus shares to be issued pursuant to the offering, will be subject to a hold period of four months plus one day from the closing date. The offering is subject to approval by the TSXV and the consent of the company's Schedule I bank secured lender.お知らせ • Jun 03Newtopia Inc. announced that it has received CAD 0.0075 million in fundingNewtopia Inc. announced that it has received a private placement of 100,000 Shares at a price of CAD 0.075 for the gross proceeds of CAD 7,500 on June 1, 2023. The transaction included participation form individual investor McCauley. After the transaction McCauley owns and controls approximately 13,994,500 Shares and 1,000,000 common share purchase warrants representing 10.0% of the shares on a partially diluted basis.お知らせ • May 25Newtopia Inc. to Report Q1, 2023 Results on May 30, 2023Newtopia Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 30, 2023株主還元NEWU.FUS HealthcareUS 市場7D0%4.0%-2.5%1Yn/a17.1%22.7%株主還元を見る業界別リターン: NEWU.FがUS Healthcare業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: NEWU.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is NEWU.F's price volatile compared to industry and market?NEWU.F volatilityNEWU.F Average Weekly Movementn/aHealthcare Industry Average Movement7.4%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.1%安定した株価: NEWU.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNEWU.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008n/aJeff Rubywww.newtopia.comNewtopia社は、主に米国でテクノロジーを活用したホールヘルスプラットフォームを展開している。同社のプラットフォームは、遺伝的、社会的、行動的洞察を活用し、代謝性疾患、糖尿病、メンタルヘルス上の課題、高血圧、体重管理、筋骨格系障害に焦点を当てた個別の予防プログラムを作成している。ニュートピア社は2008年に設立され、カナダのトロントに本社を置いている。もっと見るNewtopia Inc. 基礎のまとめNewtopia の収益と売上を時価総額と比較するとどうか。NEWU.F 基礎統計学時価総額US$623.54k収益（TTM）-US$7.26m売上高(TTM)US$6.71m0.0xP/Sレシオ0.0xPER（株価収益率NEWU.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NEWU.F 損益計算書（TTM）収益CA$6.71m売上原価CA$3.36m売上総利益CA$3.35mその他の費用CA$10.60m収益-CA$7.26m直近の収益報告Sep 30, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%NEWU.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/30 10:09終値2025/12/31 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Newtopia Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Prasath PanduranganBloom Burton & Co.Andre UddinResearch Capital CorporationJustin KeywoodStifel Canada
お知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.
お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.
お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024
お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.
お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.
お知らせ • May 15Newtopia Inc. announced that it has received CAD 1.6 million in fundingNewtopia Inc. announced that it has received CAD 1.6 million in new senior secured debt financing om May 14, 2025.
お知らせ • Aug 28Newtopia Inc., Annual General Meeting, Nov 08, 2024Newtopia Inc., Annual General Meeting, Nov 08, 2024.
お知らせ • Aug 01Newtopia Inc. to Report Q2, 2024 Results on Aug 08, 2024Newtopia Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
お知らせ • May 24Newtopia Inc. to Report Q1, 2024 Results on May 23, 2024Newtopia Inc. announced that they will report Q1, 2024 results After-Market on May 23, 2024
お知らせ • Mar 01Newtopia Inc. announced that it has received CAD 0.7465 million in fundingNewtopia Inc. a brokered private placement of 14,430,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 721,500; and a non-brokered private placement of 500,000 units at a price of CAD 0.05 per unit for gross proceeds of CAD 25,000; for aggregate gross proceeds of CAD 746,500 on February 29, 2024. The transaction included participation from Jeff Ruby, CEO of the company; Roger Poirier and Hugh G. McCauley for an aggregate of 1,110,000 units. Each unit is comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share at an exercise price of CAD 0.10 per common share, subject to adjustments in certain events, until March 1, 2027. No fees or commissions are payable to the agent in connection with the non-brokered offering. A finder acting in connection with the non-brokered offering received a finder's fee in the aggregate total amount of CAD 1,250 and an aggregate of 25,000 finder's warrants exercisable for common shares on substantially the same terms as the broker warrants. In consideration for the services provided by the agent in connection with the brokered offering, the agent received a cash fee in the aggregate amount of CAD 38,675 and 721,000 non-transferable broker warrants. Each broker warrant is exercisable for one common share at the offering price, subject to adjustments in certain events, until March 1, 2026. All securities issued in connection with the offerings are subject to a hold period which will expire on June 30, 2024, the date that is four months and one day from the closing of the offerings. The offerings are subject to final acceptance of the TSX Venture Exchange.
お知らせ • Jan 29Newtopia Launches "Glp-1 Sustain" Program to Affordably Preserve and Extend Valuable Health Benefits of Novel Weight Loss DrugsNewtopia Inc. announced GLP-1 Sustain, a companion program to specifically support and extend the dramatic clinical outcomes produced by glucagon-like-peptide-1 (GLP-1) receptor agonists and other related agonist drugs at a critical juncture in the patient journey - once a user first encounters a "weight loss plateau"i and even if users cease taking the medication entirely. In so doing, Newtopia'sGLP-1 Sustain brings to market a much-needed pathway to ensure that the many short-term health benefits of these medications may be long-lasting and that the significant costs to invest in them may in fact yield a positive ROI for payers, employers, value-based providers, and patients. Newtopia's habit change platform is already proven for its unrivaled ability to generate and maintain high levels of user-engagement for periods of two years and beyond. Newtopia leads the industry by consistently demonstrating 70% of its participants as actively engaged at 12 months, and over 60% engaged at 24 months. Through its unique engagement capabilities, Newtopia cultivates positive lifestyle habits among its participants focused on nutrition, exercise, and emotional well-being. According to published results of a randomized controlled clinical trial (RCT) on 2,835 individuals with increased waist circumference and at least one other metabolic risk factor, Newtopia's method for habit change produces significant beneficial change in several metabolic risk factors and an average weight loss of 10 pounds or 4.3% of the pre-program weight. Unpublished data from the three-year RCT further indicate that the program's weight loss benefit persists for at least three years. Such durable clinical benefits lead to an annual cost savings of at least $1,464 per participant. Leveraging this very same habit change platform, Newtopia'sGLP-1 Sustain combines genetic testing for risk factors and key behaviors with individualized live coaching, curated content, and remote monitoring from smart devices to help any GLP-1 user identify, develop, and internalize constructive lifestyle habits necessary to sustain weight loss, health, and well-being over time – whether users remain on, or ultimately stop taking these medications. GLP-1 Sustain will also produce significant annual cost savings for Newtopia clients of ~$10,000+ per participant (i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease the medication, with the average annual value-based cost of Newtopia of ~$750). At less than 1/10th the cost of these drugs, GLP-1 Sustain offers a proven, scalable, and affordable pathway to preserve the weight loss and other health benefits produced by GLP-1 medications for millions of Americans.
お知らせ • Nov 10Newtopia Inc. to Report Q3, 2023 Results on Nov 16, 2023Newtopia Inc. announced that they will report Q3, 2023 results After-Market on Nov 16, 2023
お知らせ • Oct 17Newtopia Inc. announced that it has received CAD 0.805 million in fundingOn October 16, 2023, the company announced that it has received CAD 425,000 in its second tranche. The securities issued pursuant to the offering are subject to a four month hold period that expires on February 14, 2024. The debentures issued in connection with this second tranche of the offering will mature on October 13, 2024. The company paid a finder's fee of CAD 1,800 and 15,652 non-transferable compensation options. Each compensation option is exercisable into one common share at CAD 0.115 per share, subject to adjustments in certain events, until October 13, 2025.
お知らせ • Aug 05Newtopia Inc. to Report Q2, 2023 Results on Aug 09, 2023Newtopia Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
お知らせ • Jun 29Newtopia Inc. announced that it expects to receive CAD 0.5 million in fundingNewtopia Inc. announced a non-brokered private placement of 13% 50 units of Subordinated Non-Convertible debentures at a price of CAD 10,000 for the gross proceeds of CAD 0.5 million on June 27, 2023. Each unit will be comprised of CAD10,000 principal amount of subordinated and postponed secured non-convertible debentures of the company and bonus shares. In the event that the maximum amount of debentures are issued in connection with the offering, a maximum of 1,538,461 bonus shares will be issuable in connection with the offering. The debentures will mature on the date that is 24 months from the closing date of the offering and are secured by the assets of the Company and bear interest at a rate of 13% per annum payable quarterly in arrears in cash. The company will pay to the holders of the debentures an annual work and credit maintenance fee of 2% of the principal amount in cash. The debentures and the bonus shares to be issued pursuant to the offering, will be subject to a hold period of four months plus one day from the closing date. The offering is subject to approval by the TSXV and the consent of the company's Schedule I bank secured lender.
お知らせ • Jun 03Newtopia Inc. announced that it has received CAD 0.0075 million in fundingNewtopia Inc. announced that it has received a private placement of 100,000 Shares at a price of CAD 0.075 for the gross proceeds of CAD 7,500 on June 1, 2023. The transaction included participation form individual investor McCauley. After the transaction McCauley owns and controls approximately 13,994,500 Shares and 1,000,000 common share purchase warrants representing 10.0% of the shares on a partially diluted basis.
お知らせ • May 25Newtopia Inc. to Report Q1, 2023 Results on May 30, 2023Newtopia Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 30, 2023
